Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537220 · ClinicalTrials.gov registry record · Phase 3
Oral N-acetylcysteine for Retinitis Pigmentosa
A Phase 3 study of Retinitis Pigmentosa, sponsored by Johns Hopkins University.
- Active
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
- 20
- Study locations
NCT05537220 is a Phase 3 study of Retinitis Pigmentosa that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 485 participants, above the 248-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (96% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05537220, a Phase 3 study of Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
- 20
- Study locations
Study Summary
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes to cone degeneration. N-acetylcysteine (NAC) reduces oxidative stress and in animal models of RP it slowed cone degeneration. In a phase I clinical trial in patients with RP, NAC taken by month for 6 months caused some small improvements in two different vision tests suggesting that long-term administration of NAC might slow cone degeneration in RP. NAC Attack is a clinical trial being conducted at many institutions in the US, Canada, and Europe designed to determine if taking NAC for several years provides benefit in patients with RP.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine
Study Locations (20)
California
- University of California - Davis, Department of Ophthalmology & Vision Science - Davis
- University of Southern California, Keck School of Medicine - Los Angeles
- University of California - San Francisco, Department of Ophthalmology - San Francisco
- Stanford University, Byers Eye Institute - Stanford
Florida
- Vitreo Retinal Associates - Gainesville
- University of Florida - Jacksonville, UF Health Jacksonville - Jacksonville
- University of Miami, Bascom Palmer Eye Institute - Miami
Illinois
- University Of Illinois At Chicago - Chicago
- Northwestern University - Evanston
Minnesota
- University of Minnesota, Department of Ophthalmology and Visual Neurosciences - Minneapolis
- Mayo Clinic, Department of Ophthalmology - Rochester
Georgia
- Emory University, Emory Eye Center - Atlanta
Iowa
- University of Iowa, Carver College of Medicine - Iowa City
Maryland
- Wilmer Eye Institute- Johns Hopkins University - Baltimore
Massachusetts
- Harvard University, Mass. Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2030-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05537220
The ClinicalTrials.gov registry entry for NCT05537220 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 248-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (96% higher). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05537220 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05537220 about?
NCT05537220 is a clinical study titled "Oral N-acetylcysteine for Retinitis Pigmentosa". Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After ro...
What is the current status of trial NCT05537220?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2023-10-11. Estimated completion is 2030-05.
What conditions does trial NCT05537220 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT05537220?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT05537220?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537220 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
ACTIVE NOT RECRUITING · Phase 3
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.